You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Find links to third party education sites and view recorded
sessions from global RDN experts on the latest clinical data,
patient selection criteria and RDN procedure updates.
Medscape’s education platform helps physicians learn about recent data with innovative interventional technology that can help patients achieve blood pressure control as an alternative to, or in addition to, typical treatment plans that include anti-hypertensive medications and lifestyle modifcations. CME credits available.
Radcliffe offers CME courses and webinars exploring renal denervation, clinical data, and many other topics, featuring Prof. Stefano Taddei, Prof. Atul Pathak, Prof. Andrew Sharp, Prof. Roland Schmeider, and other distinguished faculty. CME credits available.
WONDR Medical regularly introduces training resources and a wide array of video content in multiple languages at RDN:NOW.
The American Heart Association (AHA) offers a hypertension professional education series with new learning modules added regularly. Content includes webinars, spotlight series and podcasts. CME credits available.
This American College of Cardiology (ACC) education initiative platform helps learners evaluate and select evidence-based interventions and contemporary approaches for the treatment and control of hypertension. CME credits available.
Content includes webinars, podcasts, certifed cases, quick tip videos, gamifcation, patient case quizzes, and interactive cases/lessons.
Advances in renal denervation from patient selection to the procedure: EuroPCR 2022.
EuroPCR 2022 Symposium: Updates on renal denervation for the proceduralists including the latest technology and evidence, real-world procedural experience, and connecting with referring physicians.
Advancing HTN treatment beyond lifestyle modifications and medications: ESH 2022.
ESH 2022 Symposium: Hypertension experts review the evidence for safety, efficacy and durability of renal denervation; summarise the ESH consensus document; discuss the patient perspective and address common questions around renal denervation.
Clinical event reductions in high-risk hypertension patients treated with renal denervation.
Professor Roland Schmieder presents evidence that blood pressure reductions in typical hypertensive patients on medications suggest a 26% relative risk reduction in Major Adverse Cardiac Events after radiofrequency renal denervation.
Emerging consensus for renal denervation: regional perspectives.
Dr. Jose Garcia-Donaire reviews the available global consensus statements that assist with identifying patients for renal denervation.
Managing hypertension patients: is there a role for renal denervation?
NephroUpdate 2021: Professor Flavio Ribichini and Dr. Jose Antonio Garcia-Donaire discuss topics relevant to a nephrology audience, specifically covering the safety and durability of renal denervation and efficacy in CKD patients.
Renal denervation in the real-world: performance in high risk subgroups.
Professors Roland Schmieder and Markus Schlaich present patient case studies for renal denervation and discuss the role of patient preference.
Patient Profiles for renal denervation.
Professor Isabella Sudano discusses patient selection criteria for renal denervation. Multiple regional consensus statements support the use of RDN and identify appropriate patients, highlighting the importance of patient preference.
Renal denervation in a high-risk population: the Verona experience.
Professor Flavio Ribichini reviews their single-center experience demonstrating safety and efficacy of radiofrequency renal denervation in a high-risk cohort, with specific focus on CKD patients.
Patient considerations for renal denervation: the nephrology perspective from ERA 2022.
ERA 2022 Symposium: Which patients might be considered for renal denervation, including clinical evidence and real-world experience in CKD patients.
Radiofrequency renal denervation procedure.
Animation demonstrating the simple design of the Symplicity Spyral™ system and a description of the RF RDN procedure.
The science behind radiofrequency renal denervation.
Brief explanation of the mechanism behind radiofrequency RDN and the pre-clinical and clinical evidence supporting the durability of the procedure.
Renal denervation for the proceduralist: putting it into practice.
EuroPCR 2021: Professor Andrew Sharp discusses advances in the radiofrequency renal denervation (RDN) procedure including pre-clinical and clinical evidence highlighting the safety of the procedure and the long-term results.
See which types of patients could beneft from the Symplicity blood pressure procedure.
The Symplicity blood pressure procedure is supported by multiple clinical trials and a real-world patient registry.1-4
The Symplicity blood pressure procedure is changing how patients with hypertension can reduce their blood pressure.
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022;399:1401-1410.
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet. 2020;395:1444-1451.
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018;391(10137):2346.